# The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

> **NCT05816694** · PHASE2 · UNKNOWN · sponsor: **Peng Liu** · enrollment: 50 (estimated)

## Conditions studied

- Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma

## Interventions

- **DRUG:** NAB-Paclitaxel plus Cisplatin
- **DRUG:** Cisplatin plus Epirubicin plus Cyclophosphamide

## Key facts

- **NCT ID:** NCT05816694
- **Lead sponsor:** Peng Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-30
- **Primary completion:** 2024-10-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05816694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05816694, "The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05816694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*